Cybin (OTCMKTS:CYBN) Shares Up 1.8% – Should You Buy?

Cybin Inc. (OTCMKTS:CYBN)’s share price shot up 1.8% during mid-day trading on Thursday . The company traded as high as $10.40 and last traded at $10.19. 266,856 shares were traded during trading, an increase of 32% from the average session volume of 201,422 shares. The stock had previously closed at $10.01.

Cybin Price Performance

The firm has a market cap of $203.72 million, a PE ratio of -53.63 and a beta of 0.44. The stock’s fifty day moving average price is $9.85 and its 200-day moving average price is $6.39.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.